Sibrafiban (Genentech).
Sibrafiban (G-7453) is an orally active non-peptide GPIIb/IIIa antagonist, under development by Genentech and Hoffmann-La Roche, and in phase III trials as an antithrombotic. Roche intends to file for marketing approval in 1999. Merrill Lynch predicts a product launch in 2001.
Feldstein
C A
CA
Institute of Health Sciences School of Medicine, Universidad Privada, Av Las Heras 2191, Buenos Aires, Argentina.